<DOC>
	<DOCNO>NCT02152306</DOCNO>
	<brief_summary>The aim study ensure superiority Fimasartan/Amlodipine combination hypotensive effect 8 week treatment Fimasartan monotherapy patient hypertension response Fimasartan 60mg monotherapy .</brief_summary>
	<brief_title>Fimasartan/Amlodipine Combination Phase III</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>1 . Subjects voluntarily sign informed consent participate clinical trial 2 . Male Female 20 75 year old 3 . Patients essential hypertension 4 . Patients unresponsive Fimasartan 60mg monotherapy 4 week ( i.e . mean SiDBP 3 time measurement 140mmHg ≤ SiSBP &lt; 180 mmHg ) 5 . Understand trial procedure willing cooperate complete trial . 1 . Severe Hypertension patient ( SiDBP ≥ 110mmHg and/or SiSBP ≥ 180mmHg ) 2 . Subjects difference blood pressure select arm , SiDBP ≥10 mmHg SiSBP ≥20 mmHg , screen assessment 3 . Secondary hypertension patient , limit follow disease ; ( example : renovascular disease , adrenal medullary cortical hyperfunctions , coarctation aorta , hyperaldosteronism , unilateral bilateral renal artery stenosis , Cushing 's syndrome , pheochromocytoma , polycystic kidney disease , etc . ) 4 . Clinically significant renal function abnormality laboratory result screen ( i.e . serum creatine ≥ 1.5 time upper normal limit ( UNL ) ) , liver function abnormality ( ALT , AST ≥ 2 time upper normal limit ( UNL ) ) , severe fatty liver disease require medication 5 . Clinically significant Hypokalemia ( Less 3.5mmol/L ) , Hyperkalemia ( exceed 5.5mmol/L ) 6 . Subjects follow surgical internal disease may affect absorption , distribution , metabolism excretion drug condition include follow ( limited ) : history major gastrointestinal surgery include gastrectomy , gastroenterostomy bowel resection , gastrointestinal bypass graft stapling ; current active gastritis , ulcer , gastrointestinal rectal bleeding , presence active inflammatory bowel syndrome within past 12 month ; clinically significant urinary obstruction discretion investigator 7 . Subjects depletion body fluid sodium ion able correct 8 . Subjects severe insulindependent Diabetes Mellitus ( DM ) chronic DM ( HbA1c &gt; 9 % , dosage oral hypoglycemic agent modify within past 12 week , use active insulin treatment screen ) 9 . Subjects severe heart disease ( heart failure New York Heart Association ( NYHA ) Class III IV ) , history following within past 6 month ; ischemic heart disease ( e.g . angina pectoris , myocardial infarction ) , peripheral vascular disease , percutaneous transluminal coronary angioplasty , coronary artery bypass graft . 10 . Subjects clinically significant ventricular tachycardia , atrial fibrillation , atrial flutter clinical significant arrhythmia condition discretion investigator . 11 . Subjects hypertrophic obstructive cardiomyopathy , severe obstructive coronary artery disease , aortic stenosis , hemodynamically significant aortic valve stenosis , mitral valve stenosis . 12 . Subjects severe cerebrovascular disorder ( e.g . stroke , cerebral infarction cerebral hemorrhage within past 6 month ) . 13 . Subjects chronic inflammatory disease require chronic antiinflammatory therapy , Past current medical history waste disease , autoimmune disease ( e.g . rheumatoid arthritis , systemic lupus erythematosus ) connective tissue disease . 14 . Subjects know moderate malignant retinosis ( e.g . retinal hemorrhage , visual disturbance retinal microaneurysm past 6 month ) . 15 . Subjects hepatitis B ( include positive test HBsAg ) , hepatitis Cpositive . 16 . Subjects history evidence abuse drug alcohol within past 2 year . 17 . Medical history hypersensitivity angiotensin II antagonistbased drug calciumchannel blocker 18 . Subjects hereditary disorder galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption 19 . Pregnant woman lactate female 20 . Women childbearing potential use effective contraceptive method . ( Excluding subject surgically sterilize . All woman childbearing potential surgical sterilization must prove negative pregnancy test , continue use accept effective contraceptive method end study order participate . Not accepted contraceptive method : Periodic abstinence celibacy ( e.g . Basic body temperature method , menstrual cycle calculation ) , hormonal contraceptive . 21 . Subject participate another trial take investigational product within12 week screen visit 22 . Medical history kind malignant tumor include leukemia lymphoma past 5 year 23 . A subject reason specify , ineligible participate clinical trial discretion study investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Fimasartan</keyword>
	<keyword>Fimasartan Amlodipine</keyword>
	<keyword>Antihypertension</keyword>
</DOC>